How to Get Rezdiffra (Resmetirom) in Wyoming

What Is Rezdiffra and Why It Matters for Wyoming Patients

Rezdiffra (resmetirom) is a thyroid hormone receptor-beta (THR-β) selective agonist approved by the FDA on March 14, 2024, making it the first drug ever approved specifically for MASH. It is indicated for adults with noncirrhotic MASH and liver fibrosis staged F2 or F3. The drug is taken as a single oral tablet once daily.

Wyoming has a significant rural care gap. Hepatologists are concentrated in Cheyenne and Casper, leaving patients in Gillette, Sheridan, Cody, and smaller communities with limited specialist access. Telehealth prescribing closes that gap considerably.

The MAESTRO-NASH Trial: The Evidence Base

The FDA approval rested on the phase 3 MAESTRO-NASH trial (N=966), published in the New England Journal of Medicine in 2024. At 52 weeks, resmetirom 100 mg achieved MASH resolution (defined as NAS improvement ≥2 with no worsening of fibrosis) in 25.9% of patients versus 9.7% on placebo (P<0.001) [1]. Fibrosis improvement by at least one stage occurred in 29.9% on resmetirom 100 mg versus 9.7% on placebo [1].

Those are not modest numbers. A nearly threefold improvement in fibrosis stage in one year set a new benchmark for MASH pharmacotherapy [1].

Mechanism: Why THR-β Selectivity Matters

Resmetirom targets thyroid hormone receptor-beta, the isoform expressed predominantly in the liver. This selectivity avoids the cardiac and bone effects historically associated with non-selective thyroid hormone agonists. Reduced hepatic lipogenesis and accelerated fatty acid oxidation are the main downstream effects, directly addressing the metabolic drivers of steatohepatitis [2].

Who Qualifies for Rezdiffra in Wyoming

Not every patient with fatty liver disease qualifies. The FDA label specifies a narrow population, and Wyoming prescribers follow that label precisely.

Confirmed Indications

A patient must have:

• A confirmed MASH diagnosis (not simple steatosis)
• Noncirrhotic liver disease (F2 or F3 fibrosis, not F4)
• Body weight documented for dose selection (<100 kg or ≥100 kg)

Diagnosis can be established by liver biopsy or, in some clinical contexts, by validated noninvasive tests such as FIB-4 combined with MRI-PDFF or liver elastography. The FDA label does not mandate biopsy, but most Wyoming payers require histologic confirmation for prior authorization [3].

Contraindications to Screen

The FDA prescribing information lists the following as contraindications or warnings requiring evaluation before prescribing [3]:

• Decompensated cirrhosis (Child-Pugh B or C)
• Concurrent use of strong CYP2C8 inhibitors (e.g., gemfibrozil)
• Pregnancy (teratogenicity concern based on mechanism)
• Active gallbladder disease (resmetirom increased gallstone incidence in MAESTRO-NASH: 9.7% vs. 4.5% placebo) [1]

Clinicians in Wyoming must review the full prescribing information on the FDA label before initiating therapy [3].

How to Get a Rezdiffra Prescription in Wyoming: Step by Step

Getting Rezdiffra in Wyoming follows a defined clinical pathway. The steps below reflect standard practice across both in-person and telehealth settings.

Step 1: Establish Care with a Qualified Prescriber

Rezdiffra can be prescribed by any licensed Wyoming prescriber with prescriptive authority, including MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Wyoming statute grants full prescriptive authority to Advanced Practice Registered Nurses (APRNs) operating under a collaborative agreement, and PAs may prescribe under a supervising physician [4].

In practice, most Wyoming prescribers who initiate Rezdiffra are hepatologists, gastroenterologists, or internal medicine physicians with experience managing MASH. Some primary care providers have begun prescribing after completing Madrigal Pharmaceuticals' prescriber education program.

Step 2: Order Baseline Laboratory Tests

Before the first prescription is written, a standard panel is required:

• Liver function tests (ALT, AST, alkaline phosphatase, total bilirubin)
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Thyroid-stimulating hormone (TSH)
• Hemoglobin A1c (HbA1c)
• FIB-4 score (calculated from AST, ALT, platelet count, and age)
• Complete metabolic panel

If noninvasive testing is inconclusive, a liver biopsy staged by a pathologist remains the gold standard. The MAESTRO-NASH protocol required biopsy-confirmed MASH, and many Wyoming payers mirror this requirement for prior authorization [1][3].

Step 3: Prior Authorization

Most commercial insurers operating in Wyoming require prior authorization (PA) for Rezdiffra. Wyoming Medicaid does not currently cover Rezdiffra for MASH. The documentation typically required includes:

• Diagnosis codes (ICD-10: K75.81 for MASH)
• Biopsy or imaging report confirming F2, F3 fibrosis
• Current medication list confirming absence of contraindicated drugs
• BMI and body weight for dose selection
• Attestation that cirrhosis has been excluded

PA approvals in Wyoming have been running two to five business days with complete documentation. Denials are most often triggered by missing fibrosis-staging evidence.

Step 4: Specialty Pharmacy Dispensing

Rezdiffra is dispensed exclusively through specialty pharmacies. Madrigal Pharmaceuticals operates a patient support program called MASH Forward, which connects patients to contracted specialty pharmacies and may assist with co-pay support for commercially insured patients. Wyoming residents can use any nationally contracted specialty pharmacy that ships to Wyoming, including CVS Specialty, Accredo, and Optum Specialty.

Step 5: Monitoring After Initiation

After the first fill, follow-up labs are recommended at 4 weeks and 12 weeks to assess:

• ALT and AST (drug-induced liver injury signal, though rare)
• TSH (verify no unintended thyroid axis suppression)
• Lipid panel (resmetirom reduces LDL-C by approximately 16% at the 100 mg dose in MAESTRO-NASH) [1]

Telehealth Options for Rezdiffra in Wyoming

Wyoming law permits telehealth prescribing for Schedule and non-Schedule medications, including Rezdiffra, when a valid prescriber-patient relationship has been established. Rezdiffra is not a controlled substance, so there are no DEA-specific telehealth restrictions that apply to its prescription [5].

Which Telehealth Platforms Operate in Wyoming

Several national telehealth platforms have licensed providers in Wyoming who can evaluate and prescribe for MASH, including HealthRX. A Wyoming-licensed prescriber must conduct the visit, review imaging and laboratory results, and document the encounter in compliance with Wyoming Board of Medicine standards.

The Wyoming Board of Medicine requires that a telehealth encounter for prescribing meet the same standard of care as an in-person visit. A text-only or asynchronous questionnaire alone does not meet that standard for a complex MASH diagnosis [4].

What to Expect in a Telehealth Visit for Rezdiffra

A typical telehealth encounter for Rezdiffra evaluation runs 30 to 45 minutes and covers:

• Review of prior liver imaging and biopsy reports
• Current symptom burden (fatigue, right upper quadrant discomfort)
• Metabolic comorbidities (type 2 diabetes, dyslipidemia, obesity)
• Medication reconciliation for CYP2C8 drug interactions
• Baseline labs (ordered before the visit or reviewed if recently completed)

If baseline labs have not yet been drawn, the telehealth provider can order them to a local Wyoming lab (LabCorp and Quest Diagnostics both have patient service centers in Cheyenne, Casper, Gillette, and Laramie), then schedule a follow-up visit to finalize the prescription.

Pharmacy Access and 503A Compounding in Wyoming

Specialty Pharmacy Dispensing

Rezdiffra is a brand-name drug with no FDA-approved generic. It must be dispensed as the Madrigal-manufactured product. National specialty pharmacies ship to Wyoming addresses, typically with two-day delivery via temperature-controlled packaging where required.

503A Compounding Pharmacies in Wyoming

Wyoming-licensed 503A compounding pharmacies are legally permitted to compound medications for individual patients when a specific medical need exists that is not met by an FDA-approved product. However, resmetirom is an FDA-approved drug in a commercially available form. Compounding an FDA-approved drug in its approved indication is generally not permitted under Section 503A of the Federal Food, Drug, and Cosmetic Act because doing so would essentially copy a commercially available product [6].

A 503A pharmacy in Wyoming can compound resmetirom only if a patient has a documented allergy to an excipient in the commercial tablet, the prescriber documents a specific medical need, and the pharmacy does not use a bulk drug substance that is on the FDA's "demonstrably difficult to compound" list. In practice, this scenario is rare. Wyoming patients should not expect 503A compounding as a routine access pathway [6].

Cost, Insurance Coverage, and Patient Assistance in Wyoming

Commercial Insurance

Rezdiffra carries a list price of approximately $47,400 per year (2024 wholesale acquisition cost). Most commercial plans in Wyoming with pharmacy benefit coverage will consider PA approval when documentation is complete. United Healthcare, Aetna, BlueCross BlueShield of Wyoming, and Cigna have all published coverage policies for Rezdiffra as of mid-2025.

Wyoming Medicaid

Wyoming Medicaid does not currently cover Rezdiffra for MASH. Medicaid beneficiaries should discuss alternative options with their prescriber, including enrollment in Madrigal's patient assistance program or eligibility for clinical trial enrollment.

MASH Forward Patient Support Program

Madrigal Pharmaceuticals offers MASH Forward, a hub program that provides:

• Benefits investigation and prior authorization support
• Co-pay assistance (commercially insured patients may pay as little as $0/month subject to eligibility caps)
• Free medication for uninsured or underinsured patients meeting income criteria

Wyoming patients can enroll through their prescriber's office or directly at Madrigal's patient support line.

Clinical Guidelines Supporting Rezdiffra Use

The American Association for the Study of Liver Diseases (AASLD) 2023 Practice Guidance on MASH states: "Pharmacologic treatment should be reserved for patients with MASH confirmed by liver biopsy (or by validated noninvasive tests where available) who are at high risk of disease progression, including those with significant fibrosis (stage F2 or greater)" [7]. Rezdiffra fits precisely within that recommendation.

The Endocrine Society has not issued a contradictory position on THR-β agonists in the context of MASH treatment, and no major guideline body has recommended against resmetirom use in appropriately selected patients [8].

The FDA label's approved language reads: "REZDIFFRA is indicated in adults for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate-to-advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) to be used along with diet and exercise" [3]. Diet and lifestyle modification remain required adjuncts. Prescribers in Wyoming should document counseling on reduced-calorie diet and physical activity at each visit.

Wyoming-Specific Considerations for Rezdiffra Access

Geographic Barriers and Solutions

Wyoming ranks among the least densely populated states in the country. The nearest hepatology center for patients in towns like Rawlins, Pinedale, or Lusk may be three to four hours away. Telehealth prescribing, combined with local lab draws and specialty pharmacy home delivery, makes Rezdiffra practically accessible to nearly all Wyoming ZIP codes.

Lab Draw Sites in Wyoming

Patients who need baseline labs can use the following sites without a specialist referral:

• LabCorp: Cheyenne, Casper, Gillette, Laramie, Rock Springs
• Quest Diagnostics: Cheyenne, Casper
• Wyoming Medical Center lab network: walk-in phlebotomy in Casper

Results are typically available within 24 to 48 hours and can be shared directly with a telehealth prescriber via a patient portal.

Transferring an Existing Prescription to Wyoming

Patients who initiated Rezdiffra in another state and have relocated to Wyoming can transfer their prescription to a Wyoming-licensed specialty pharmacy. The prescribing physician must hold an active Wyoming license or a Wyoming telehealth license to continue issuing refills. If the original prescriber is not licensed in Wyoming, the patient should establish care with a Wyoming-licensed provider who can review the chart and issue new prescriptions.